SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY (HCM)

Clinical trials for SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY (HCM) explained in plain language.

Never miss a new study

Get alerted when new SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY (HCM) trials appear

Sign up with your email to follow new studies for SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY (HCM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Heart Drug's Long-Term safety under the microscope in major study

Disease control ENROLLING_BY_INVITATION

This study aims to gather long-term safety information on the experimental drug aficamten for people with symptomatic hypertrophic cardiomyopathy (HCM), a condition where the heart muscle thickens. It will follow 900 participants who have already taken aficamten in a previous tri…

Matched conditions: SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY (HCM)

Phase: PHASE2, PHASE3 • Sponsor: Cytokinetics • Aim: Disease control

Last updated Mar 31, 2026 12:11 UTC

SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY (HCM)

Get alerted when new SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY (HCM) trials appear

Heart Drug's Long-Term safety under the microscope in major study